Reckitt Benckiser’s Mead Johnson unit and Abbott Laboratories have been ordered to face a new trial in the US over ...

Reckitt Benckiser is moving forward with the sale of its nutrition operations housing the Mead Johnson infant-formula ...

Back in October, a jury found North Chicago-based Abbott and Reckitt’s formula subsidiary Mead Johnson not responsible for a baby developing necrotizing enterocolitis, or NEC, from their ...

Reckitt Benckiser is continuing to assess options for its nutrition operations housing the Mead Johnson infant-formula business. After describing nutrition as "non-core" in July as part of a ...

Reckitt has shown a medium-term uptrend since April 2024, outperforming peers, but litigation risks from Mead Johnson remain substantial, making the stock a hold. Reckitt's strategic focus on high ...

Health and Human Services Secretary Robert F. Kennedy Jr. is planning to meet Tuesday with executives of companies that make ...

Mead Johnson is deciding whether to invest in Zeeland or elsewhere in the country, the city wrote in a news release.

The stable outlook reflects Moody’s base case expectations that Reckitt’s gross debt/EBITDA leverage will stay at or below 2.5x, and that the company’s competitive position will continue to support ...

As trade war intensifies, Reckitt may be more exposed than some rivals Some investors fear Reckitt may be forced to raise its prices in the United States or face higher costs as its low ...

Reckitt Benckiser’s Mead Johnson unit and Abbott Laboratories have been ordered to face a new trial in the US over allegations their premature infant formula can cause a serious gut condition.